Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor Corporation (NASDAQ: DXR) announced that five new hospitals have adopted its BVA-100 blood volume diagnostic tool to enhance fluid management in heart failure patients as of Q1 2023. This expansion, involving key healthcare organizations in New Jersey, Virginia, Mississippi, and Florida, signals significant growth in blood volume analysis sales. The BVA test has demonstrated substantial benefits, including an 82% reduction in 30-day mortality and a 56% decrease in readmissions for heart failure patients. CEO Michael Feldschuh emphasizes the growing need for effective management solutions as the population of heart failure patients is projected to rise from six million to over eight million in the coming years.
Daxor Corporation (NYSE: DXR) presented new data on its BVA-100 diagnostic at the Technology Heart Failure Therapeutics Conference, showcasing its role in enhancing therapy for heart failure patients. A study indicated that less than half of patients displayed concordant pressure-volume changes during CardioMEMS monitoring, suggesting reliance on pressure alone may be inadequate for guiding heart failure management. This underscores the value of BVA-100 in accurately assessing blood volume, which has been linked to improved patient outcomes including reduced mortality and hospital readmissions. Daxor aims to revolutionize heart failure treatment through precise blood volume analysis.
Daxor Corporation (NYSE: DXR) has announced promising new data from a pilot randomized control trial validating the accuracy of its BVA-100 diagnostic in managing heart failure therapy. The study, conducted at Duke Heart, highlighted a potential reduction in hospital stay by 2.7 days (P<0.09) for patients receiving BVA-guided care. The results, presented at the Technology Heart Failure Therapeutics Conference, indicated a significant discrepancy between physician assessments and BVA results. Daxor aims to leverage this data to support larger-scale clinical studies, reinforcing the effectiveness of blood volume analysis in improving heart failure treatment outcomes.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement, updated shareholders in a letter dated March 1, 2023, from CEO Michael Feldschuh. The company reported a 36.95% increase in net assets to $28,969,469 with significant progress in commercialization, product development, and clinical outcomes. A notable launch is the next-generation portable blood volume analyzer, validated to be three times faster than the current model. Daxor expects an uptick in revenue from single-use diagnostics kits, projected to increase 59.5% in 2022. Additionally, partnerships with the U.S. Department of Defense and other entities are aimed at enhancing product availability and market penetration.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced a significant increase in its net asset value (NAV) per share, rising to $6.75 for fiscal 2022, up 36.95% from $5.24 in 2021. The company reported a 20.5% rise in unaudited revenues, driven by a 59.5% increase in sales of its blood volume analysis diagnostic systems. With new partnerships and contracts, including with the U.S. DOD and NIH, Daxor plans to launch its next-generation system in 2023. Upcoming clinical trials are expected to further validate the efficacy of its technology.
Daxor Corporation (Nasdaq: DXR) will report its financial results for the year ending December 31, 2022 on March 1, 2023, after market close. The company will also hold a conference call on March 2, 2023, at 9 AM EST, where President Michael Feldschuh and CFO Robert Michel will discuss the results and ongoing corporate initiatives. Daxor, a leader in blood volume measurement technology, aims to enhance healthcare with its FDA-cleared BVA-100 diagnostic test, which has significantly impacted patient outcomes in heart failure and critical care. The company is conducting multicenter trials supported by the NIH, focusing on COVID-19 and heart failure treatment.
Daxor Corporation (Nasdaq: DXR) announced the appointment of Linda Cooper as Vice President of Project Management, effective February 17, 2023. With over 30 years of experience in the medical device industry, Cooper will lead development projects, including next-generation systems and oversee operations at the Oak Ridge facility. Previously, she held senior roles at OsteoCentric Technologies and Integra LifeSciences, managing product launches from design to regulatory clearance. Cooper expressed enthusiasm for optimizing procedures and planning for future growth as the company prepares for its significant technology launch in 20 years.
Daxor Corporation (Nasdaq: DXR) has become a corporate member of the Heart Failure Society of America (HFSA) to enhance engagement with heart failure leaders. This collaboration aims to improve patient outcomes as heart failure affects over 6 million Americans, with nearly 1 million deaths annually. CEO Michael Feldschuh highlighted the opportunity to advance their BVA-100 technology for better product adoption. The membership allows access to HFSA leadership and year-round brand promotion, with goals to expand their user base and products in 2023.
Daxor Corporation (Nasdaq: DXR) announced its participation in the 2023 Critical Care Congress by the Society for Critical Care Medicine, scheduled from January 21 to 24 in San Francisco.
CEO Michael Feldschuh emphasized the congress as a significant opportunity to expand business, focusing on the critical care market's demand for volume management solutions. Daxor's BVA-100® (Blood Volume Analyzer) has shown promising results in improving patient outcomes, including a 66% reduction in mortality in surgical ICU settings. The company aims to enhance healthcare through optimal fluid management and has conducted over 60,000 tests at leading hospitals.
Daxor Corporation (Nasdaq: DXR) announces a groundbreaking study published in the Journal of Cardiovascular Translational Research. The research highlights the inaccuracy of pressure measures in assessing blood volume in heart failure patients compared to the BVA-100 blood test. Results showed a significant lack of correlation between PADP and total blood volume (TBV) measurements, emphasizing the 98% accuracy of direct volume measurement. The study reinforces the importance of blood volume analysis in improving patient outcomes and management in heart failure, supported by extensive published research.